Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367183 | 1.00 | LMNA (0.63) | LMNANPSR1USP30NPC1MEN1 | |
| SCHEMBL12327657 | 0.97 | LMNA (0.59) | LMNANPSR1USP30NPC1MEN1 | |
| SCHEMBL12098332 | 0.92 | LMNA (0.63) | LMNANPSR1USP30NPC1MEN1 | |
| SCHEMBL7609243 | 0.92 | LMNA (0.63) | LMNANPSR1USP30NPC1MEN1 | |
| SCHEMBL38657837 | 0.92 | LMNA (0.63) | LMNANPSR1USP30NPC1MEN1 | |
| SCHEMBL31315648 | 0.89 | LMNA (0.66) | LMNANPSR1USP30NPC1MEN1 | |
| SCHEMBL12600537 | 0.89 | LMNA (0.59) | LMNANPSR1USP30NPC1MEN1 | |
| SCHEMBL38659170 | 0.88 | LMNA (0.64) | LMNANPSR1USP30NPC1MEN1 | |
| SCHEMBL38656332 | 0.88 | LMNA (0.64) | LMNANPSR1USP30NPC1MEN1 | |
| SCHEMBL3835665 | 0.86 | LMNA (0.70) | LMNANPSR1USP30NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017076201-A1 | HCV INHIBITORS, PREPARATION METHOD AND USE THEREOF | 江苏豪森药业集团有限公司 | 2017-05-11 | — | — | WO | disclosed |
| US-20150218194-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-9006387-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2853531-A2 | Antiviral compounds | AbbVie Bahamas Ltd. (BS) | 2015-04-01 | — | — | EP | disclosed |
| EP-2455376-B1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | ABBVIE BAHAMAS LTD (BS) | 2014-11-26 | — | — | EP | disclosed |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES | 2014-10-23 | — | — | US | disclosed |
| EP-2337781-B1 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | ABBVIE BAHAMAS LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2368890-B9 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-10-30 | — | — | EP | disclosed |
| EP-2628481-A1 | Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV | AbbVie Bahamas Ltd. (BS) | 2013-08-21 | — | — | EP | disclosed |
| EP-2368890-B1 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-04-17 | — | — | EP | disclosed |
| EP-2455376-A1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2368890-A1 | Hepatitis C virus inhibitors | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | LMNA 3118/4885NPSR1 4296/4885USP30 1963/4885 |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | LMNA 3118/4885NPSR1 4296/4885USP30 1963/4885 |
| US-20150218194-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | LMNA 3118/4885NPSR1 4296/4885USP30 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.